Journal article

Priority actions for the non-communicable disease crisis

R Beaglehole, R Bonita, R Horton, C Adams, G Alleyne, P Asaria, V Baugh, H Bekedam, N Billo, S Casswell, M Cecchini, R Colagiuri, S Colagiuri, T Collins, S Ebrahim, M Engelgau, G Galea, T Gaziano, R Geneau, A Haines Show all

Lancet | Published : 2011

Abstract

The UN High-Level Meeting on Non-Communicable Diseases (NCDs) in September, 2011, is an unprecedented opportunity to create a sustained global movement against premature death and preventable morbidity and disability from NCDs, mainly heart disease, stroke, cancer, diabetes, and chronic respiratory disease. The increasing global crisis in NCDs is a barrier to development goals including poverty reduction, health equity, economic stability, and human security. The Lancet NCD Action Group and the NCD Alliance propose five overarching priority actions for the response to the crisis - leadership, prevention, treatment, international cooperation, and monitoring and accountability - and the delive..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Wellcome Trust


Funding Acknowledgements

PA has received grants from Wellcome Trust Clinical PhD Fellowship. SE has received grants from the Wellcome Trust, and royalties from 18 McGraw Hill for editing a book. RI-I is the editor of The Lancet. TG has received consultancy payments from Family Health International and 19 Inter-American Development Bank; and payment for lectures, including lectures on speakers bureaus, from Network for Continuing Medical 20 Education. BN has received consultancy payments from Bayer, payment for lectures including service on speakers bureaus from Allergan, and 21 royalties for a book published by Karolinska University Press. BN's institute has received money for consultancy from Syngis, Servier, Bayer, 22 Photothera, and Boehringer-Ingelheim. JT has received or has grants pending from Corporate Partners, Pfizer, Wiley, Sanofi-Aventis, Varian Medical Systems, Roche, Boehringer Ingelheim, Novartis, Slender, 23 Merck, Eli Lilly, Heng Rui, and Irmet. The other authors declare that they have no conflicts of interest. We thank the National Heart Forum for providing financial, technical, and administrative support for the production of this report. The authors alone are responsible for the views expressed in this report and they do not necessarily represent the decisions, policy, or views of WHO, the World Bank, the OECD, or those of the member countries of these organisations.